查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1954191

抗菌素抗藥性市場分析及預測（至2035年）：類型、產品類型、服務、技術、應用、最終用戶、流程、部署類型、解決方案

Antimicrobial Resistance Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Application, End User, Process, Deployment, Solutions
出版日期: | 出版商: Global Insight Services | 英文 349 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

預計抗菌素抗藥性市場將從2024年的63億美元成長到2034年的128億美元，複合年成長率約為8.6%。抗菌素抗藥性市場涵蓋了應對病原體對標準療法產生抗藥性這一日益嚴峻挑戰的解決方案，包括新型抗生素、診斷技術以及噬菌體療法和益生菌等替代療法。隨著抗藥性問題日益嚴重，公眾意識的提高和監管支持的加強，使得人們迫切需要創新藥物和技術來對抗感染疾病。該市場呈現出成長勢頭，凸顯了研發、戰略合作以及政府主導的各項舉措對於減輕抗藥性在全球範圍內的影響的重要性。

由於迫切需要新的治療方法來對抗抗藥性病原體，抗菌藥物抗藥性市場正經歷顯著成長。在治療方法領域，抗生素細分市場成長最快，這主要得益於針對多重抗藥性細菌的先進製劑的研發。抗病毒藥物細分市場成長速度位居第二，這主要得益於為應對病毒抗藥性挑戰而開發的新型藥物類別。在診斷領域，能夠快速且準確地識別抗藥性感染疾病的快速診斷測試佔據主導。緊隨其後的是分子診斷，它在檢測抗藥性基因方面具有更高的靈敏度和特異性。對抗菌藥物管理計劃日益成長的需求也進一步推動了市場成長，凸顯了最佳化抗生素使用的重要性。疫苗作為一種預防措施正受到越來越多的關注，其中細菌疫苗已成為一個重要的細分市場。開發針對抗藥性菌株的創新疫苗對於市場的長期永續性至關重要。製藥公司與研究機構之間的合作對於促進創新和拓展治療選擇至關重要。

市場區隔
種類 抗生素、抗病毒藥物、抗黴菌藥、抗寄生蟲藥、消毒劑
產品 藥品、疫苗、診斷試劑、感染預防產品
服務 諮詢、測試服務、監控服務、教育和培訓
科技 基因組學、蛋白質組學、奈米技術、生物資訊學
應用領域 本院獲得性感染、社區型感染
最終用戶 醫院和診所、製藥公司、研究機構、政府和監管機構
過程 藥物發現、藥物開發、臨床試驗和監管核准
實施表格 本機部署、雲端部署
解決方案 抗菌藥物管理計畫、感染控制方案

抗菌藥物抗藥性市場正經歷市場佔有率、定價和產品發布方面的動態變化。隨著對創新解決方案的日益關注，新參與企業正在挑戰現有領導企業。定價策略競爭日益激烈，各公司都在努力平衡價格可負擔性和最尖端科技進步。新產品的推出旨在滿足未被滿足的需求、提高療效並最大限度地減少抗藥性。市場產品種類繁多，各公司透過策略行銷和分銷管道爭奪市場主導地位。競爭基準分析表明，主要參與者不斷創新以保持其競爭優勢。監管影響至關重要，嚴格的指導方針影響產品開發和市場准入。各公司透過投資合規和遵守國際標準來應對這些法規。在技​​術進步和人們對抗菌藥物抗藥性日益成長的認知的推動下，市場蓄勢待發，即將迎來成長。隨著各公司尋求擴展產品系列和鞏固市場地位，策略聯盟和併購活動日益頻繁。

主要趨勢和促進因素：

抗菌素抗藥性（AMR）市場正經歷顯著成長，這主要得益於人們對抗生素濫用和過度使用的認知不斷提高。各國政府和衛生組織已將AMR列為重要的公共衛生議題，並加強了研發投入。這一趨勢推動了診斷技術和新型抗菌藥物的研發。抗藥性感染疾病的日益普遍也促使人們開發新的治療策略，這也是市場成長的關鍵促進因素。製藥業正在探索對抗抗藥性的替代方法，例如噬菌體療法和抗菌肽。此外，人工智慧和機器學習等先進技術在藥物發現過程中的應用，使得高效識別有前景的候選藥物成為可能。同時，法規結構的發展旨在簡化新抗菌藥物的核准流程，鼓勵企業投資這個充滿挑戰卻又前景看好的市場。公私合營也夥伴關係出現，凸顯了全球攜手對抗AMR的努力。對於能夠適應不斷變化的抗菌素抗藥性情況並進行創新的企業而言，機會比比皆是。

目錄

第1章執行摘要

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機遇
  • 市場限制
  • 複合年均成長率：成長分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章 細分市場分析

  • 市場規模及預測：依類型
    • 抗生素
    • 抗病毒藥物
    • 抗真菌劑
    • 抗寄生蟲藥物
    • 消毒劑
  • 市場規模及預測：依產品分類
    • 製藥
    • 疫苗
    • 診斷試劑盒
    • 感染預防產品
  • 市場規模及預測：依服務分類
    • 諮詢
    • 檢查室檢測
    • 監控服務
    • 教育和培訓
  • 市場規模及預測：依技術分類
    • 基因組學
    • 蛋白質體學
    • 奈米科技
    • 生物資訊學
  • 市場規模及預測：依應用領域分類
    • 院內感染
    • 社區型感染
  • 市場規模及預測：依最終用戶分類
    • 醫院和診所
    • 製藥公司
    • 研究所
    • 政府和監管機構
  • 市場規模及預測：依製程分類
    • 藥物發現
    • 藥物研發
    • 臨床試驗
    • 監管部門核准
  • 市場規模及預測：依發展狀況
    • 本地部署
    • 基於雲端的
  • 市場規模及預測：按解決方案分類
    • 抗菌藥物管理計劃
    • 感染控制解決方案

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地區
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲地區

第6章 市場策略

  • 需求與供給差距分析
  • 貿易和物流限制
  • 價格、成本和利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 法規概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 主要企業的策略

第8章 公司簡介

  • Melinta Therapeutics
  • Nabriva Therapeutics
  • Paratek Pharmaceuticals
  • Achaogen
  • Iterum Therapeutics
  • Venatorx Pharmaceuticals
  • Aridis Pharmaceuticals
  • Motif Bio
  • Spero Therapeutics
  • Scynexis
  • Cidara Therapeutics
  • Summit Therapeutics
  • Entasis Therapeutics
  • Forge Therapeutics
  • Debiopharm Group
  • Macrolide Pharmaceuticals
  • Qpex Biopharma
  • Bugworks Research
  • Antabio
  • Nosopharm

第9章：關於我們

簡介目錄
Product Code: GIS31569

Antimicrobial Resistance Market is anticipated to expand from $6.3 billion in 2024 to $12.8 billion by 2034, growing at a CAGR of approximately 8.6%. The Antimicrobial Resistance Market encompasses solutions addressing the growing challenge of pathogens resistant to standard treatments. This includes novel antibiotics, diagnostics, and alternative therapies such as phage therapy and probiotics. As resistance escalates, there is an urgent demand for innovative drugs and technologies to combat infections, driven by increased awareness and regulatory support. The market is poised for growth, emphasizing research and development, strategic collaborations, and government initiatives to mitigate resistance impact globally.

The Antimicrobial Resistance Market is experiencing notable growth, driven by the urgent need for novel therapeutics to combat resistant pathogens. Within the therapeutic segment, the antibiotics sub-segment is the top performer, fueled by the development of advanced formulations targeting multi-drug resistant strains. The second highest performing sub-segment is the antivirals, as new drug classes are designed to address viral resistance challenges. In the diagnostics segment, rapid diagnostic tests lead the way, providing timely and precise identification of resistant infections. Molecular diagnostics follow closely, offering enhanced sensitivity and specificity in detecting resistance genes. The rising demand for antimicrobial stewardship programs further propels market growth, emphasizing the importance of optimizing antibiotic use. Preventative measures, such as vaccines, are gaining momentum, with bacterial vaccines being the leading sub-segment. The development of innovative vaccines targeting resistant strains is crucial for long-term market sustainability. Collaborative efforts between pharmaceutical companies and research institutions are pivotal, fostering innovation and expanding treatment options.

Market Segmentation
TypeAntibiotics, Antivirals, Antifungals, Antiparasitics, Disinfectants
ProductDrugs, Vaccines, Diagnostic Kits, Infection Prevention Products
ServicesConsulting, Laboratory Testing, Surveillance Services, Education and Training
TechnologyGenomics, Proteomics, Nanotechnology, Bioinformatics
ApplicationHospital-acquired Infections, Community-acquired Infections
End UserHospitals and Clinics, Pharmaceutical Companies, Research Laboratories, Government and Regulatory Bodies
ProcessDrug Discovery, Drug Development, Clinical Trials, Regulatory Approval
DeploymentOn-premise, Cloud-based
SolutionsAntimicrobial Stewardship Programs, Infection Control Solutions

The antimicrobial resistance market is experiencing dynamic shifts in market share, pricing, and product launches. A growing emphasis on innovative solutions is prompting new entrants to challenge established leaders. Pricing strategies are increasingly competitive, with companies seeking to balance affordability with cutting-edge advancements. New product launches are focusing on addressing unmet needs, enhancing efficacy, and minimizing resistance. The market is characterized by a diverse range of products, each vying for prominence through strategic marketing and distribution channels. Competition benchmarking reveals a landscape where key players are continuously innovating to maintain their competitive edge. Regulatory influences play a crucial role, with stringent guidelines shaping product development and market entry. Companies are navigating these regulations by investing in compliance and aligning with global standards. The market is poised for growth, driven by technological advancements and heightened awareness of antimicrobial resistance. Strategic partnerships and mergers are becoming prevalent, as firms seek to expand their portfolios and enhance their market position.

Geographical Overview:

The antimicrobial resistance market is witnessing varied growth across different regions, with unique opportunities emerging. North America leads the market, propelled by substantial investments in research and development and a robust healthcare infrastructure. The region's focus on innovative solutions to combat resistance has spurred significant advancements. Europe follows closely, driven by stringent regulations and a strong emphasis on public health initiatives. The region's collaborative efforts in research and policy-making are fostering a conducive environment for market expansion. Asia Pacific is rapidly becoming a key growth pocket, with increasing awareness and governmental support driving the market. Emerging economies like India and China are at the forefront, investing heavily in healthcare infrastructure and novel antimicrobial solutions. Latin America and the Middle East & Africa are also showing promising potential. These regions are increasingly recognizing the importance of addressing antimicrobial resistance, with growing investments in healthcare systems and international collaborations.

The global antimicrobial resistance (AMR) market is intricately influenced by tariffs, geopolitical risks, and evolving supply chain paradigms. In Japan and South Korea, strategic investments in biotechnology and pharmaceutical innovation are mitigating tariff impacts, while China accelerates its focus on localizing drug production to counteract export restrictions. Taiwan, with its robust pharmaceutical manufacturing base, remains a pivotal player but is vulnerable to regional tensions. The global AMR market is witnessing robust growth due to heightened awareness and regulatory support, yet faces supply chain vulnerabilities. By 2035, the market is poised for significant expansion, driven by technological advancements and international collaborations. Middle East conflicts continue to exert pressure on global energy prices, indirectly affecting manufacturing and logistics costs within the AMR supply chain.

Key Trends and Drivers:

The Antimicrobial Resistance (AMR) market is experiencing substantial growth driven by increasing awareness of antibiotic misuse and overuse. Governments and health organizations are prioritizing AMR as a critical public health issue, leading to heightened investments in research and development. This trend is fostering innovations in diagnostics and novel antimicrobial agents. A significant driver is the rising prevalence of drug-resistant infections, which necessitates the development of new treatment strategies. The pharmaceutical industry is exploring alternative approaches, such as bacteriophage therapy and antimicrobial peptides, to combat resistant strains. Another trend is the integration of advanced technologies like AI and machine learning in drug discovery, enhancing the efficiency of identifying potential candidates. Additionally, regulatory frameworks are evolving to streamline the approval process for new antimicrobials, encouraging companies to invest in this challenging yet promising market. Partnerships between public and private sectors are also emerging, focusing on collaborative efforts to address AMR globally. Opportunities abound for companies that can innovate and adapt to the dynamic landscape of antimicrobial resistance.

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Application
  • 2.6 Key Market Highlights by End User
  • 2.7 Key Market Highlights by Process
  • 2.8 Key Market Highlights by Deployment
  • 2.9 Key Market Highlights by Solutions

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Antibiotics
    • 4.1.2 Antivirals
    • 4.1.3 Antifungals
    • 4.1.4 Antiparasitics
    • 4.1.5 Disinfectants
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Drugs
    • 4.2.2 Vaccines
    • 4.2.3 Diagnostic Kits
    • 4.2.4 Infection Prevention Products
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Consulting
    • 4.3.2 Laboratory Testing
    • 4.3.3 Surveillance Services
    • 4.3.4 Education and Training
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 Genomics
    • 4.4.2 Proteomics
    • 4.4.3 Nanotechnology
    • 4.4.4 Bioinformatics
  • 4.5 Market Size & Forecast by Application (2020-2035)
    • 4.5.1 Hospital-acquired Infections
    • 4.5.2 Community-acquired Infections
  • 4.6 Market Size & Forecast by End User (2020-2035)
    • 4.6.1 Hospitals and Clinics
    • 4.6.2 Pharmaceutical Companies
    • 4.6.3 Research Laboratories
    • 4.6.4 Government and Regulatory Bodies
  • 4.7 Market Size & Forecast by Process (2020-2035)
    • 4.7.1 Drug Discovery
    • 4.7.2 Drug Development
    • 4.7.3 Clinical Trials
    • 4.7.4 Regulatory Approval
  • 4.8 Market Size & Forecast by Deployment (2020-2035)
    • 4.8.1 On-premise
    • 4.8.2 Cloud-based
  • 4.9 Market Size & Forecast by Solutions (2020-2035)
    • 4.9.1 Antimicrobial Stewardship Programs
    • 4.9.2 Infection Control Solutions

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Application
      • 5.2.1.6 End User
      • 5.2.1.7 Process
      • 5.2.1.8 Deployment
      • 5.2.1.9 Solutions
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Application
      • 5.2.2.6 End User
      • 5.2.2.7 Process
      • 5.2.2.8 Deployment
      • 5.2.2.9 Solutions
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Application
      • 5.2.3.6 End User
      • 5.2.3.7 Process
      • 5.2.3.8 Deployment
      • 5.2.3.9 Solutions
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Application
      • 5.3.1.6 End User
      • 5.3.1.7 Process
      • 5.3.1.8 Deployment
      • 5.3.1.9 Solutions
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Application
      • 5.3.2.6 End User
      • 5.3.2.7 Process
      • 5.3.2.8 Deployment
      • 5.3.2.9 Solutions
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Application
      • 5.3.3.6 End User
      • 5.3.3.7 Process
      • 5.3.3.8 Deployment
      • 5.3.3.9 Solutions
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Application
      • 5.4.1.6 End User
      • 5.4.1.7 Process
      • 5.4.1.8 Deployment
      • 5.4.1.9 Solutions
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Application
      • 5.4.2.6 End User
      • 5.4.2.7 Process
      • 5.4.2.8 Deployment
      • 5.4.2.9 Solutions
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Application
      • 5.4.3.6 End User
      • 5.4.3.7 Process
      • 5.4.3.8 Deployment
      • 5.4.3.9 Solutions
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Application
      • 5.4.4.6 End User
      • 5.4.4.7 Process
      • 5.4.4.8 Deployment
      • 5.4.4.9 Solutions
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Application
      • 5.4.5.6 End User
      • 5.4.5.7 Process
      • 5.4.5.8 Deployment
      • 5.4.5.9 Solutions
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Application
      • 5.4.6.6 End User
      • 5.4.6.7 Process
      • 5.4.6.8 Deployment
      • 5.4.6.9 Solutions
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Application
      • 5.4.7.6 End User
      • 5.4.7.7 Process
      • 5.4.7.8 Deployment
      • 5.4.7.9 Solutions
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Application
      • 5.5.1.6 End User
      • 5.5.1.7 Process
      • 5.5.1.8 Deployment
      • 5.5.1.9 Solutions
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Application
      • 5.5.2.6 End User
      • 5.5.2.7 Process
      • 5.5.2.8 Deployment
      • 5.5.2.9 Solutions
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Application
      • 5.5.3.6 End User
      • 5.5.3.7 Process
      • 5.5.3.8 Deployment
      • 5.5.3.9 Solutions
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Application
      • 5.5.4.6 End User
      • 5.5.4.7 Process
      • 5.5.4.8 Deployment
      • 5.5.4.9 Solutions
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Application
      • 5.5.5.6 End User
      • 5.5.5.7 Process
      • 5.5.5.8 Deployment
      • 5.5.5.9 Solutions
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Application
      • 5.5.6.6 End User
      • 5.5.6.7 Process
      • 5.5.6.8 Deployment
      • 5.5.6.9 Solutions
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Application
      • 5.6.1.6 End User
      • 5.6.1.7 Process
      • 5.6.1.8 Deployment
      • 5.6.1.9 Solutions
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Application
      • 5.6.2.6 End User
      • 5.6.2.7 Process
      • 5.6.2.8 Deployment
      • 5.6.2.9 Solutions
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Application
      • 5.6.3.6 End User
      • 5.6.3.7 Process
      • 5.6.3.8 Deployment
      • 5.6.3.9 Solutions
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Application
      • 5.6.4.6 End User
      • 5.6.4.7 Process
      • 5.6.4.8 Deployment
      • 5.6.4.9 Solutions
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Application
      • 5.6.5.6 End User
      • 5.6.5.7 Process
      • 5.6.5.8 Deployment
      • 5.6.5.9 Solutions

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Melinta Therapeutics
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Nabriva Therapeutics
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Paratek Pharmaceuticals
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Achaogen
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Iterum Therapeutics
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Venatorx Pharmaceuticals
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Aridis Pharmaceuticals
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Motif Bio
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Spero Therapeutics
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Scynexis
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Cidara Therapeutics
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Summit Therapeutics
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Entasis Therapeutics
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Forge Therapeutics
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Debiopharm Group
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Macrolide Pharmaceuticals
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Qpex Biopharma
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Bugworks Research
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Antabio
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Nosopharm
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us